GW Pharmaceuticals plc (GWPH,GWP.L), Monday said it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme or GBM, which is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA. This study comes after various pre-clinical research conducted by GW in the field of glioma.
The trial is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. Secondary endpoints are additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.